The Translational Reserarch in Hepatic Oncology IDIBAPS group, led by Dr. Josep M. Llovet, in collaboration with Dr. Roser Pinyol and 8 more researchers, participates in a European project to identify the molecular mechanisms that have a direct impact on the development of hepatocellular carcinoma (HCC). The HEP-CAR project will evaluate the role of these mechanisms in different liver diseases leading to HCC -the infection by hepatitis B and C, overweight or alcohol-. This research initiative, coordinated by the University of Freiburg and in which ten European academic centers are involved, is part of Horizon 2020, the European Comission framework programme for research and innovation, and it is endowed with a budget of 5.7 million euros, one of them corresponding to IDIBAPS.
IDIBAPS researchers have participated in a pioneering study in hepatocellular carcinoma, the most common liver cancer, in which all the genetic alterations that occur in this type of tumor have been characterized. In an article published in the journal Nature Genetics scientists provide a complete overview of the disease and these genetic alterations associated with the etiology and clinical characteristics, the proposed treatments for patients approved for other cancers, which could be applied in each case. Dr. Josep Maria Llovet, ICREA professor at the IDIBAPS Hepatic Oncology Group and director of the Liver Cancer Program at the Icahn School of Medicine at Mount Sinai (New York), and Dr. Roser Pinyol, researcher at the same group, have participated in this article led by Dr. Jessica Zucman-Rossi, from the INSERM-Paris.
Prof Josep M Llovet
Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, Chen J, Poon RT, Zender L, Lowe SW, Hong W, Luk JM.
Berdasco M, Esteller M.
Gaujoux S, Pinson S, Gimenez-Roqueplo AP, Amar L, Ragazzon B, Launay P, Meatchi T, Libé R, Bertagna X, Audebourg A, Zucman-Rossi J, Tissier F, Bertherat J.